Shareholders Approve Significant Increase in Equity Incentive Plan
KRMD sits 58% above its 52-week low of $2.625.
Summary
KORU Medical Systems shareholders approved an amendment to increase the shares available under its equity incentive plan, enabling future equity awards but also creating potential dilution.
Key Events · Corporate Governance and Compliance · KRMD
-
Equity Incentive Plan Expanded
Shareholders approved an amendment to the 2024 Omnibus Equity Incentive Plan, increasing the number of shares available for future equity awards. This follows the proposal outlined in the DEF 14A filed on April 9, 2026.
-
Director Elections Confirmed
All nominated directors, including R. John Fletcher, Robert A. Cascella, Donna French, Joseph M. Manko, Jr., Shahriar Matin, Linda Tharby, and Edward Wholihan, were elected to the Company's board of directors.
-
Executive Compensation Approved
Shareholders provided advisory approval for the compensation of the Company's executive officers and voted for future advisory votes on executive compensation to occur annually.
-
Auditor Ratified
The appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2026 fiscal year was ratified by shareholders.
Analysis · KRMD · Industrial Applications And Services
KORU Medical Systems shareholders approved an amendment to the 2024 Omnibus Equity Incentive Plan, increasing the pool of shares available for equity awards. This approval, following the DEF 14A filing on April 9, 2026, confirms the company's ability to issue more shares for compensation, which will result in future dilution for existing shareholders.
At the time of this filing, KRMD was trading at $4.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $190.2M. The 52-week trading range was $2.63 to $6.61. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.